- Home
- AKBA vs FOR Comparison
AKBA vs FOR Comparison
Compare AKBA & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- FOR
- Stock Information
- Founded
- AKBA 2007
- FOR 2005
- Country
- AKBA United States
- FOR United States
- Employees
- AKBA N/A
- FOR N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- FOR Real Estate
- Sector
- AKBA Health Care
- FOR Finance
- Exchange
- AKBA Nasdaq
- FOR Nasdaq
- Market Cap
- AKBA 958.6M
- FOR 1.0B
- IPO Year
- AKBA 2014
- FOR 2007
- Fundamental
- Price
- AKBA $3.97
- FOR $21.85
- Analyst Decision
- AKBA Strong Buy
- FOR Strong Buy
- Analyst Count
- AKBA 5
- FOR 3
- Target Price
- AKBA $6.90
- FOR $30.33
- AVG Volume (30 Days)
- AKBA 5.2M
- FOR 142.9K
- Earning Date
- AKBA 08-07-2025
- FOR 07-22-2025
- Dividend Yield
- AKBA N/A
- FOR N/A
- EPS Growth
- AKBA N/A
- FOR N/A
- EPS
- AKBA N/A
- FOR 3.29
- Revenue
- AKBA $184,909,000.00
- FOR $1,471,000,000.00
- Revenue This Year
- AKBA $26.88
- FOR $3.95
- Revenue Next Year
- AKBA $44.34
- FOR $8.86
- P/E Ratio
- AKBA N/A
- FOR $6.35
- Revenue Growth
- AKBA N/A
- FOR N/A
- 52 Week Low
- AKBA $0.92
- FOR $18.00
- 52 Week High
- AKBA $4.08
- FOR $37.21
- Technical
- Relative Strength Index (RSI)
- AKBA 62.71
- FOR 63.22
- Support Level
- AKBA $3.48
- FOR $20.79
- Resistance Level
- AKBA $3.77
- FOR $21.92
- Average True Range (ATR)
- AKBA 0.17
- FOR 0.67
- MACD
- AKBA -0.04
- FOR 0.16
- Stochastic Oscillator
- AKBA 62.82
- FOR 94.36
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.